Analyst Price Targets — VCYT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 5, 2026 2:28 pm | Subbu Nambi | Guggenheim | $50.00 | $42.95 | TheFly | Veracyte price target raised to $50 from $45 at Guggenheim |
| December 1, 2025 9:36 pm | — | Morgan Stanley | $48.00 | $46.39 | TheFly | Veracyte assumed with an Underweight at Morgan Stanley |
| November 5, 2025 2:25 pm | Lu Li | UBS | $48.00 | $43.64 | TheFly | Veracyte price target raised to $48 from $42 at UBS |
| November 5, 2025 6:58 am | Kyle Mikson | Canaccord Genuity | $43.00 | $36.12 | StreetInsider | Veracyte, Inc (VCYT) PT Raised to $43 at Canaccord Genuity |
| October 20, 2025 9:35 am | Kyle Mikson | Canaccord Genuity | $40.00 | $35.83 | TheFly | Veracyte initiated with a Hold at Canaccord |
| August 8, 2025 7:19 pm | Tejas Savant | Morgan Stanley | $28.00 | $27.37 | TheFly | Veracyte price target lowered to $28 from $29 at Morgan Stanley |
| November 7, 2024 12:21 pm | Mike Matson | Needham | $44.00 | $35.85 | StreetInsider | Veracyte, Inc (VCYT) PT Raised to $44 at Needham |
| August 12, 2024 9:21 am | Tejas Savant | Morgan Stanley | $26.00 | $29.41 | TheFly | Veracyte price target raised to $26 from $21 at Morgan Stanley |
| May 4, 2022 11:06 am | — | Morgan Stanley | $23.00 | $21.00 | Benzinga | Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $23 |
| May 4, 2022 6:26 am | — | Needham | $26.00 | $21.46 | Benzinga | Needham Maintains Buy on Veracyte, Lowers Price Target to $26 |
Latest News for VCYT
Artisan Partners Limited Partnership raised its holdings in shares of Veracyte, Inc. (NASDAQ: VCYT) by 16.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,370,467 shares of the biotechnology company's stock after acquiring an additional 1,048,692 shares during the quarter. Artisan
VCYT posts a 47% y/y Q4 earnings jump and 18.5% revenue growth, beats estimates, lifts margins and sees shares rise after hours.
The portfolio generated strong absolute returns in Q4 and 2025 but trailed the MSCI All Country World Small Mid Index over each period. Stock selection in health care was the strongest contributor to performance for both the quarter and year. Management highlighted strong demand for high-speed optical components supporting AI-driven data center growth, alongside improving margins.
Veracyte, Inc. (VCYT) Q4 2025 Earnings Call Transcript
Veracyte (VCYT) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.36 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VCYT.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.